Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- XTLY +13.4%, VDTH +13%, FRO +2.7%, BNS +1.1%
M&A news:
- CCN +9.9% (to be acquired by First Data (FDC) for $15.00 per share)
Other news:
- PTGX +42.9% (enters into a worldwide license and collaboration agreement with Janssen Biotech (JNJ), will receive an upfront payment of $50 mln; sees having financial resources to fund all ongoing and planned research and development activities until the middle of 2019)
- BIOS +11.4% (to continue to provide certain core product lines to UnitedHealthcare (UNH) beyond September 30)
- ECYT +8.1% (to announce updated data on EC1456 and EC1169 at ASCO)
- NIHD +8.1% (continued strength)
- ARRY +6.6% (Array Biopharma and Bristol-Myers Squibb (BMY) enter clinical research collaboration)
- CYAD +6.4% (receives additional patent in US for TCR-deficient allogeneic CAR-T cells)
- BHVN +4.2% (completes enrollment in its clinical study of trigriluzole; expects to submit a new drug application to the FDA in early 2018)
- PME +3.7% (CEO announces intention to buy at least 1 mln shares of the co)
- JUNO +2.1% (Director disclosed purchase of 20000 shares worth ~ $500K)
- JD +1.2% (positive profile in Barrons)
- CROX +0.8% (positive profile in Barrons)
Analyst comments:
- PSDV +3.2% (initiated with a Buy at Rodman & Renshaw)
- ZNGA +2.9% (upgraded to Overweight from Neutral at Piper Jaffray)
- AZO +1.2% (upgraded to Buy from Neutral at Goldman)
- T +0.5% (upgraded to Neutral from Sell at MoffettNathanson)